News Related to Prophylactic Vaccines

Related coverage linked through entity extraction aliases.

Moderna and Merck Advance mRNA Cancer Vaccine Trial in First-Line Lung Cancer

Feb 24, 2026

Moderna and Merck are recruiting patients for a Phase 2 trial testing V940, an mRNA-based cancer vaccine, combined with Keytruda and chemotherapy as first-line treatment for metastatic squamous non-small cell lung cancer.

mRNA Therapy Market Projected to Reach USD 70 Billion by 2035 Amid Expanding Applications

Feb 12, 2026

The mRNA therapy market is forecast to grow from USD 13.6 billion in 2025 to USD 70.0 billion by 2035 at a 17.8% CAGR, driven by expanding applications beyond vaccines into oncology, rare diseases, and infectious disease treatments including genital herpes.